ArticleAmerican journal of epidemiology2011
Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly.
Article in American journal of epidemiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed.
- Autoimmune conditions and primary central nervous system lymphoma risk among older adults.British journal of haematology · 2020Trial
- Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study.BMC nephrology · 2012Trial
- Cancer risk associated with abatacept among older individuals with rheumatoid arthritis in the United States.JNCI cancer spectrum · 2026Article
- Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism.Blood advances · 2026Article
- Modern sources of controls in case-control studies.American journal of epidemiology · 2025Article
- Pretransplant screening and lower incidence of breast and prostate cancers among organ transplant recipients in the United States.JNCI cancer spectrum · 2025Article
- Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis.Rheumatology (Oxford, England) · 2025Article
- Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer.Cancer medicine · 2025Observational
- The role of artificial intelligence in pandemic responses: from epidemiological modeling to vaccine development.Molecular biomedicine · 2025Review
- Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Association between diabetes and subsequent malignancy risk among older breast cancer survivors.JNCI cancer spectrum · 2024Article
- The causal associations of circulating lipids with Barrett's Esophagus and Esophageal Cancer: a bi-directional, two sample mendelian randomization analysis.Human genomics · 2024Article
- Autoimmune disease and the risk of anal cancer in the US population aged 66 years and over.Journal of the National Cancer Institute · 2024Article
- The development and validation of automated machine learning models for predicting lymph node metastasis in Siewert type II T1 adenocarcinoma of the esophagogastric junction.Frontiers in medicine · 2024Article
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival.British journal of cancer · 2023Article
- Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.JAMA network open · 2023Article
- Autoimmune conditions and pancreatic cancer risk in older American adults.International journal of cancer · 2023Article
- Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study.Cancers · 2022Article
- Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence Among Older Women With Breast Cancer.Journal of the National Cancer Institute · 2022Article
- Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States.JNCI cancer spectrum · 2022Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer is an important cause of morbidity in the elderly, and many medical conditions and treatments influence cancer risk. The Surveillance, Epidemiology, and End Results (SEER)-Medicare database can be used to conduct population-based case-control studies that elucidate the etiology of cancer among the US elderly. SEER-Medicare links data on malignancies ascertained through SEER cancer registries to claims from Medicare, the US government insurance program for people over age 65 years. Under one approach described herein, elderly cancer cases are ascertained from SEER data (1987-2005). Matched controls are selected from a 5% random sample of Medicare beneficiaries. Risk factors of interest, including medical conditions and procedures, are identified by using linked Medicare claims. Strengths of this design include the ready availability of data, representative sampling from the US elderly population, and large sample size (e.g., under one scenario: 1,176,950 cases, including 221,389 prostate cancers, 185,853 lung cancers, 138,041 breast cancers, and 124,442 colorectal cancers; and 100,000 control subjects). Limitations reflect challenges in exposure assessment related to Medicare claims: restricted range of evaluable risk factors, short time before diagnosis/selection for ascertainment, and inaccuracies in claims. With awareness of limitations, investigators have in SEER-Medicare data a valuable resource for epidemiologic research on cancer etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.